We are live on ! Find out more
TXG icon

10x Genomics
TXG

268 hedge funds and large institutions have $3.19B invested in 10x Genomics in 2022 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 75 increasing their positions, 89 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 28

30% more capital invested

Capital invested by funds: $2.45B → $3.19B (+$742M)

15% more funds holding

Funds holding: 233 → 268 (+35)

1.02% more ownership

Funds ownership: 90.57% → 91.59% (+1%)

10% more call options, than puts

Call options by funds: $42.7M | Put options by funds: $38.9M

16% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 89

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
268
Holders Change
+35
Holders Change %
+15.02%
% of All Funds
4.31%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.08%
New
67
Increased
75
Reduced
89
Closed
28
Calls
$42.7M
Puts
$38.9M
Net Calls
+$3.79M
Net Calls Change
+$5.4M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$36.3M
2
Millennium Management
Millennium Management
New York
+$32.7M
3
Wolverine Trading
Wolverine Trading
Illinois
+$30.7M
4
Man Group
Man Group
United Kingdom
+$17.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$16.2M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.7M
2
AAM
Ardevora Asset Management
United Kingdom
-$15.5M
3
FCMI
Foresite Capital Management II
California
-$12.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11M
5
BAMCO Inc
BAMCO Inc
New York
-$9.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$376M -$3.52M -107,676 -1%
Baillie Gifford & Co
2
Baillie Gifford & Co
United Kingdom
$313M +$5.19M +158,847 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$307M +$4.76M +145,652 +2%
BlackRock
4
BlackRock
New York
$194M +$7.42M +227,061 +4%
AIM
5
ARK Investment Management
Florida
$157M -$8.51M -260,247 -6%
Sands Capital Management
6
Sands Capital Management
Virginia
$117M -$6.03M -184,394 -5%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$117M -$16.7M -509,836 -14%
SIM
8
SRS Investment Management
New York
$110M – – –
GIM
9
Generation Investment Management
United Kingdom
$92.9M -$1.88M -57,577 -2%
NAMA
10
Nikko Asset Management Americas
New York
$79.4M -$957K -29,270 -1%
Sumitomo Mitsui Trust Group
11
Sumitomo Mitsui Trust Group
Japan
$79.4M -$957K -29,270 -1%
CS
12
Credit Suisse
Switzerland
$77.8M -$642K -19,630 -0.9%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$73.3M -$11M -337,054 -14%
Citadel Advisors
14
Citadel Advisors
Florida
$53.3M +$36.3M +1,108,820 +312%
BCM
15
Brown Capital Management
Maryland
$53M -$5.28M -161,463 -10%
FCMI
16
Foresite Capital Management II
California
$49.5M -$12.9M -395,000 -23%
State Street
17
State Street
Massachusetts
$49M -$594K -18,168 -1%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$48.1M +$2.07M +63,324 +5%
JP Morgan Chase
19
JP Morgan Chase
New York
$46M +$1.81M +55,496 +5%
Millennium Management
20
Millennium Management
New York
$44.2M +$32.7M +999,487 +467%
MCAV
21
Meritech Capital Associates V
California
$38.7M – – –
SW
22
SVB Wealth
Massachusetts
$35.8M -$743K -22,725 -2%
Wolverine Trading
23
Wolverine Trading
Illinois
$34.2M +$30.7M +939,091 New
Norges Bank
24
Norges Bank
Norway
$32.6M +$2.8M +85,712 +11%
RI
25
RTW Investments
New York
$31.8M +$7.62M +232,938 +36%
1
2 3 4 5

TXG Hedge Fund Activity: Q4 2022 in Review

268 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2022, worth a combined $3.19B — up 30% from $2.45B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new TXG positions and 28 closed out — a net gain of 39 holders — while 75 added to existing stakes and 89 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $36.3M. The largest seller was Fidelity Investments, cutting an estimated $16.7M.

  • 268 institutional investors held 10x Genomics (TXG) as of Q4 2022, up from 233 in Q3 2022.
  • Funds reported $3.19B of 10x Genomics stock for Q4 2022, up 30% quarter-over-quarter.
  • 67 funds opened new 10x Genomics positions in Q4 2022 and 28 closed out, a net change of +39 holders.
  • The largest 10x Genomics buyer in Q4 2022 was Citadel Advisors, an estimated $36.3M added.
  • The largest 10x Genomics seller in Q4 2022 was Fidelity Investments, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2022.